TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28810721

Group type: EXPERIMENTAL
Intervention: Low-dose sirolimus (SRL) with extended-release tacrolimus (ER-TAC)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Mycophenolate mofetil (MMF) with extended-release tacrolimus (ER-TAC)
Number of subjects: 158
Study: 25391263

Group type: EXPERIMENTAL
Intervention: CRS followed by HIPEC and then systemic chemotherapy (Group A)
Number of subjects: 120

Group type: COMPARATOR
Intervention: CRS only and systemic chemotherapy (Group B)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: HIPEC group
Number of subjects: 120

Group type: COMPARATOR
Intervention: Non-HIPEC group
Number of subjects: 120
Study: 23030695

Group type: EXPERIMENTAL
Intervention: Cetuximab plus best supportive care (BSC)
Number of subjects: 453

Group type: COMPARATOR
Intervention: Best supportive care (BSC) alone
Number of subjects: 453
Study: 21768319

Group type: EXPERIMENTAL
Intervention: Mother-child bed-sharing at ages 1 to 3 years
Number of subjects: 944
Study: 19812865

Group type: EXPERIMENTAL
Intervention: Nutrient dense drink
Number of subjects: 176

Group type: COMPARATOR
Intervention: Placebo drink
Number of subjects: 176
Study: 17079523

Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative treatment (OMT)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sham manipulative treatment
Number of subjects: 16
Study: 14643625

Group type: EXPERIMENTAL
Intervention: 12-week functional exercise programme (40-min sessions, twice a week)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 12-week functional exercise programme
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (no exercise programme)
Number of subjects: 26
Study: 10502644

Group type: EXPERIMENTAL
Intervention: Obstacles of different heights
Number of subjects: 15
Study: 8596480

Group type: EXPERIMENTAL
Intervention: Palmitic acid diet
Number of subjects: 12

Group type: COMPARATOR
Intervention: Stearic acid diet
Number of subjects: 12
Study: 1790040

Group type: EXPERIMENTAL
Intervention: Booster mailing intervention two weeks after screening
Number of subjects: 272

Group type: COMPARATOR
Intervention: Control group (no booster mailing)
Number of subjects: 272
Study: 7120377

Group type: EXPERIMENTAL
Intervention: Self-instructional strategies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: External self-instructional condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Relaxation training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Attention control group
Number of subjects: 0
Study: 31092118

Group type: EXPERIMENTAL
Intervention: Traditional high intensity interval training (TRAD, n=10)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Periodized high intensity interval training (PER, n=9)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Traditional high intensity interval training (TRAD)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Periodized high intensity interval training (PER)
Number of subjects: 19
Study: 27565045

Group type: EXPERIMENTAL
Intervention: Validated diagnostic prediction model for AHF using patient age, clinician pretest probability for AHF, and NT-proBNP as a continuous value.
Number of subjects: 197

Group type: COMPARATOR
Intervention: Standard care (blinded arm).
Number of subjects: 197
Study: 25223178

Group type: EXPERIMENTAL
Intervention: Guilu Erxian Glue Cataplasm (GEGC)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 21798674

Group type: EXPERIMENTAL
Intervention: Trazodone
Number of subjects: 137

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 137
Study: 20412426

Group type: EXPERIMENTAL
Intervention: Udenafil 100 mg
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study: 18056819

Group type: EXPERIMENTAL
Intervention: Subsyndromal depressive symptoms (SSD)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Minimal or no depressive symptoms (Control)
Number of subjects: 204
Study: 16287350

Group type: EXPERIMENTAL
Intervention: Football equipment on indoor rubberized track
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Football equipment on outdoor natural-grass field
Number of subjects: 68

Group type: COMPARATOR
Intervention: Minimal apparel on indoor rubberized track
Number of subjects: 68

Group type: COMPARATOR
Intervention: Minimal apparel on outdoor natural-grass field
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Football equipment for backs
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Football equipment for linemen
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Running on grass for backs
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Running on grass for linemen
Number of subjects: 68
Study: 12297166

Group type: EXPERIMENTAL
Intervention: CRP>5mg/l
Number of subjects: 113

Group type: COMPARATOR
Intervention: CRP<5mg/l
Number of subjects: 113
Study: 10078671

Group type: EXPERIMENTAL
Intervention: Neostigmine 50 microg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Neostigmine 6.25 to 50 microg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Neostigmine (all doses)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Bupivacaine spinal anesthesia (control)
Number of subjects: 18
Study: 7733038

Group type: EXPERIMENTAL
Intervention: High stearate (HS) diet: 2.4% energy as palmitic acid (16:0) and 7.3% energy as stearic acid (18:0)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Low stearate (LS) diet: 1.5% energy as stearic acid (18:0) and 7.3% energy as palmitic acid (16:0)
Number of subjects: 10
Study: 2158140

Group type: EXPERIMENTAL
Intervention: CY 222 (15,000 U AXa IC) administered via subcutaneous injection once daily for 14 days
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 30
Study: 6280332

Group type: EXPERIMENTAL
Intervention: suloctidil (Sulocton, Continental Pharma)
Number of subjects: 31

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 31
Study: 31194707

Group type: EXPERIMENTAL
Intervention: Hydrocolloid dressing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Silver hydrofiber dressing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Paraffin gauze dressing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antimicrobial biguanide foam dressing
Number of subjects: 0
Study: 27632215

Group type: EXPERIMENTAL
Intervention: Dexamethasone intravitreal implant (DEX implant) 0.7 mg every 5 months
Number of subjects: 363

Group type: COMPARATOR
Intervention: Ranibizumab 0.5 mg administered as per European Summary of Product Characteristics
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: Dexamethasone intravitreal implant (DEX implant)
Number of subjects: 363

Group type: COMPARATOR
Intervention: Ranibizumab
Number of subjects: 363
Study: 27514246

Group type: EXPERIMENTAL
Intervention: Light exercise (yoga or similar)
Number of subjects: 620

Group type: EXPERIMENTAL
Intervention: Moderate exercise (aerobic conditioning)
Number of subjects: 620

Group type: EXPERIMENTAL
Intervention: Vigorous exercise (aerobic conditioning)
Number of subjects: 620

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 620
Study: 24333244

Group type: EXPERIMENTAL
Intervention: Bipolar transurethral resection
Number of subjects: 147

Group type: COMPARATOR
Intervention: Monopolar transurethral resection
Number of subjects: 147
Study: 22293876

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg intravenously, twice daily for 5 days
Number of subjects: 25

Group type: COMPARATOR
Intervention: Pantoprazole 40 mg intravenously, twice daily for 5 days
Number of subjects: 25
Study: 19059324

Group type: EXPERIMENTAL
Intervention: Novel fixed dose combination tablet containing 300mg zidovudine (AZT) and 160mg lamivudine (3TC)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Duovir tablet
Number of subjects: 18
Study: 17660644

Group type: EXPERIMENTAL
Intervention: Compomer
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Resin-modified GIC
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Composite resin
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (Intact teeth)
Number of subjects: 60
Study: 17868806

Group type: EXPERIMENTAL
Intervention: Ejection Fraction (EF) ≤ 30%
Number of subjects: 674

Group type: EXPERIMENTAL
Intervention: Ejection Fraction (EF) > 30% with other risk factors
Number of subjects: 674
Study: 15613293

Group type: EXPERIMENTAL
Intervention: Mesh placed in a sublay position
Number of subjects: 54

Group type: COMPARATOR
Intervention: Conventional stoma
Number of subjects: 54
Study: 11105479

Group type: EXPERIMENTAL
Intervention: Witnesses' confidence ratings
Number of subjects: 144

Group type: COMPARATOR
Intervention: Investigators' confidence ratings
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Witnessing conditions (good vs poor)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Investigators' discrimination ability
Number of subjects: 144
Study: 8814372

Group type: EXPERIMENTAL
Intervention: 17 Gy in two fractions (524 patients)
Number of subjects: 1048

Group type: EXPERIMENTAL
Intervention: 39 Gy in 13 fractions (153 patients)
Number of subjects: 1048

Group type: COMPARATOR
Intervention: Other regimens (371 patients)
Number of subjects: 1048
Study: 1462992

Group type: EXPERIMENTAL
Intervention: Cytodiagnostic urinalysis
Number of subjects: 77
Study: 6204534

Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfacetamide-polymyxin B
Number of subjects: 0

Group type: COMPARATOR
Intervention: Polymyxin B-neomycin-gramicidin (Neosporin, control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trimethoprim-polymyxin B
Number of subjects: 0
Study: 31046806

Group type: EXPERIMENTAL
Intervention: No Touch (NT) saphenous vein graft harvesting
Number of subjects: 250

Group type: COMPARATOR
Intervention: Conventional (CON) saphenous vein graft harvesting
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: No Touch (NT) saphenous vein graft harvesting (aggregated data)
Number of subjects: 250
Study: 29959799

Group type: EXPERIMENTAL
Intervention: Jintrolong® 0.01 mg/kg
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Jintrolong® 0.06 mg/kg
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Jintrolong® 0.2 mg/kg
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Jintrolong® 0.5 mg/kg
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Jintrolong® 0.8 mg/kg
Number of subjects: 64

Group type: COMPARATOR
Intervention: Conventional rhGH 0.067 mg/kg
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Jintrolong® 0.1 mg/kg
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Jintrolong® 0.4 mg/kg
Number of subjects: 64
Study: 26575983

Group type: EXPERIMENTAL
Intervention: MenACWY-TT
Number of subjects: 0

Group type: COMPARATOR
Intervention: MenC-CRM197 (control)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Men-PS (control)
Number of subjects: 0
Study: 24168074

Group type: EXPERIMENTAL
Intervention: Goal Management Training (GMT) - 21 hours
Number of subjects: 38

Group type: COMPARATOR
Intervention: Wait-list condition (Control)
Number of subjects: 38
Study: 22760383

Group type: EXPERIMENTAL
Intervention: Single-incision technique with two suture anchors
Number of subjects: 91

Group type: COMPARATOR
Intervention: Double-incision technique with transosseous drill holes
Number of subjects: 91
Study: 19461031

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg per day
Number of subjects: 4731

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4731
Study: 17805088

Group type: EXPERIMENTAL
Intervention: CAF/CHO
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: PLA/CHO
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: CAF/PLA
Number of subjects: 12
Study: 15741486

Group type: EXPERIMENTAL
Intervention: Divalproex (N=20)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo (N=32)
Number of subjects: 52
Study: 12236459

Group type: EXPERIMENTAL
Intervention: Brief, individualized alcohol abuse prevention program
Number of subjects: 155

Group type: COMPARATOR
Intervention: No‐treatment control group
Number of subjects: 155
Study: 9823973

Group type: EXPERIMENTAL
Intervention: CHARTWEL 60 Gy in 16 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: CHARTWEL 54 Gy in 16 days
Number of subjects: 0
Study: 7865417

Group type: EXPERIMENTAL
Intervention: Double-headed toothbrush
Number of subjects: 30

Group type: COMPARATOR
Intervention: Single-headed toothbrush
Number of subjects: 30
Study: 2919762

Group type: EXPERIMENTAL
Intervention: methohexital
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: etomidate
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: midazolam
Number of subjects: 64
Study: 31894603

Group type: EXPERIMENTAL
Intervention: Leaf Expander appliance
Number of subjects: 101

Group type: COMPARATOR
Intervention: Hyrax expansion screw
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 101
Study: 31695332

Group type: EXPERIMENTAL
Intervention: CoQ10 liquid supplementation (100 mg/day for 3 months)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 29246188

Group type: EXPERIMENTAL
Intervention: Amoxicillin 750 mg orally three times a day for 100 days
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo orally three times a day for 100 days
Number of subjects: 160
Study: 25342855

Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent (EES)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 77
Study: 25029835

Group type: EXPERIMENTAL
Intervention: Pizhen treatment, once a week for 2 weeks (1 treatment course)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Acupuncture massage instrument, 20 minutes once a day for 2 weeks
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Pizhen treatment
Number of subjects: 116

Group type: COMPARATOR
Intervention: Acupuncture massage instrument
Number of subjects: 116
Study: 22939637

Group type: EXPERIMENTAL
Intervention: Transoral incisionless fundoplication (TIF)
Number of subjects: 100
Study: 19527383

Group type: EXPERIMENTAL
Intervention: Education program
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Education with pill count
Number of subjects: 320

Group type: COMPARATOR
Intervention: Pill count alone
Number of subjects: 320
Study: 17311735

Group type: EXPERIMENTAL
Intervention: Partner notification by practice nurses
Number of subjects: 19773

Group type: EXPERIMENTAL
Intervention: Home-based postal chlamydia screening
Number of subjects: 19773

Group type: COMPARATOR
Intervention: Screening men and women annually
Number of subjects: 19773

Group type: EXPERIMENTAL
Intervention: Nucleic acid amplification tests
Number of subjects: 19773

Group type: COMPARATOR
Intervention: Screening
Number of subjects: 19773

Group type: EXPERIMENTAL
Intervention: Home-sampling
Number of subjects: 19773
Study: 15337655

Group type: EXPERIMENTAL
Intervention: Sertraline (50-150 mg/day)
Number of subjects: 370

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 370
Study: 14575396

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 20

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 20
Study: 10599961

Group type: EXPERIMENTAL
Intervention: Hepcon/HMS system
Number of subjects: 114

Group type: COMPARATOR
Intervention: ACT group
Number of subjects: 114
Study: 7842421

Group type: EXPERIMENTAL
Intervention: Mammography screening in women aged 40-49 years
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mortality analyses eliminating advanced cases detected by physical examination
Number of subjects: 0
Study: 1903723

Group type: EXPERIMENTAL
Intervention: Desmopressin
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 6264825

Group type: EXPERIMENTAL
Intervention: Cl2MDP (1600 mg daily for 12 weeks)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (12 weeks)
Number of subjects: 14
Study: 31477359

Group type: EXPERIMENTAL
Intervention: Normal Saline (NS)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Conventional Active Drug Mixture (CADM)
Number of subjects: 48
Study: 29969808

Group type: EXPERIMENTAL
Intervention: EPLBD alone
Number of subjects: 200

Group type: COMPARATOR
Intervention: EPLBD with EST
Number of subjects: 200
Study: 29030802

Group type: EXPERIMENTAL
Intervention: Stretta treatment
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (PPIs)
Number of subjects: 20
Study: 24913739

Group type: EXPERIMENTAL
Intervention: Facemask (FM) therapy
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Double-plate appliance/facemask (DPA-FM) therapy
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study: 24360924

Group type: EXPERIMENTAL
Intervention: Parent-led group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Staff-led group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 22672576

Group type: EXPERIMENTAL
Intervention: Pedometer intervention (STEP) including one group meeting, log-monitored pedometer-use, and six e-mail messages from OHC
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Pedometer intervention (STEP)
Number of subjects: 241

Group type: COMPARATOR
Intervention: Control group (COMP)
Number of subjects: 241
Study: 19392952

Group type: EXPERIMENTAL
Intervention: Multifactorial 12-month fall prevention program
Number of subjects: 591
Study: 17884371

Group type: EXPERIMENTAL
Intervention: Triple antiplatelet therapy (aspirin, clopidogrel, and cilostazol)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Dual antiplatelet therapy (aspirin and clopidogrel)
Number of subjects: 500
Study: 14687046

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid 300 mg twice daily
Number of subjects: 46

Group type: COMPARATOR
Intervention: S-adenosyl-l-methionine 500 mg twice daily
Number of subjects: 46
Study: 12452381

Group type: EXPERIMENTAL
Intervention: Electroacupuncture on the Zusanli (St 36) points
Number of subjects: 15

Group type: COMPARATOR
Intervention: Intravenous atropine before electroacupuncture
Number of subjects: 15
Study: 9408704

Group type: EXPERIMENTAL
Intervention: Contraceptive vaginal ring (CVR) releasing 20 micrograms ethinyl estradiol and 1 mg of norethindrone acetate daily over two successive cycles with three different insertion regimens
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Contraceptive vaginal ring (CVR)
Number of subjects: 159
Study: 7685429

Group type: EXPERIMENTAL
Intervention: Laser prostatectomy with Urolase right angle firing neodymium:YAG laser fiber
Number of subjects: 25

Group type: COMPARATOR
Intervention: Standard transurethral electroresection of the prostate
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 25
Study: 3032224

Group type: EXPERIMENTAL
Intervention: Cyclosporin A
Number of subjects: 60

Group type: COMPARATOR
Intervention: Azathioprine and prednisone
Number of subjects: 60
Study: 31210085

Group type: EXPERIMENTAL
Intervention: Tracheal breathing sounds analysis using a support vector machine (SVM) classifier
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Tracheal breathing sounds analysis with anthropometric parameters and a voting procedure
Number of subjects: 122
Study: 27396240

Group type: EXPERIMENTAL
Intervention: eGFR in G1 (120≤eGFR)
Number of subjects: 1407

Group type: EXPERIMENTAL
Intervention: eGFR in G2 (90≤eGFR<120)
Number of subjects: 1407

Group type: EXPERIMENTAL
Intervention: Rapid decliners (annual eGFR decline rate≥3ml/min/1.73m2)
Number of subjects: 1407

Group type: EXPERIMENTAL
Intervention: GFR<60ml/min/1.73m2 at follow-up
Number of subjects: 1407
Study: 25202842

Group type: EXPERIMENTAL
Intervention: Educational program targeting coaches' knowledge and management of eating disorders, nutrition, and weight regulation.
Number of subjects: 76
Study: 23383975

Group type: EXPERIMENTAL
Intervention: Saw palmetto (320 mg gelcap daily for 24 weeks, then 2 gelcaps daily for 24 weeks, then 3 gelcaps daily for 24 weeks)
Number of subjects: 306

Group type: COMPARATOR
Intervention: Placebo (matching placebo gelcaps for the same durations)
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Both groups (saw palmetto and placebo)
Number of subjects: 306
Study: 22608494

Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation (vitamin E 800 mg, C 500 mg, zinc 40 mg) for 6 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard therapy (pegylated interferon combined with ribavirin)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 0
Study: 19095492

Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES) combined with traditional swallowing training
Number of subjects: 26

Group type: COMPARATOR
Intervention: Sham stimulation plus traditional swallowing training
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: NMES combined with traditional swallowing training
Number of subjects: 26
Study: 17150287

Group type: EXPERIMENTAL
Intervention: 23-valent Pneumococcal Polysaccharide Vaccine (23vPPV) during the third trimester or at delivery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vaccination at 7 months post delivery
Number of subjects: 0
Study: 15373174

Group type: EXPERIMENTAL
Intervention: Permixon 320 mg/day
Number of subjects: 124

Group type: COMPARATOR
Intervention: Tamsulosin 0.4 mg/day
Number of subjects: 124
Study: 11255445

Group type: EXPERIMENTAL
Intervention: Rivastigmine treatment (2 to 12 mg/d) for 26 weeks after 26 weeks of placebo treatment
Number of subjects: 187
Study: 9663162

Group type: EXPERIMENTAL
Intervention: Intervention (training, feedback, and prompts)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 54
Study: 7944817

Group type: EXPERIMENTAL
Intervention: Warm antegrade cardioplegia
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Tepid antegrade cardioplegia
Number of subjects: 72

Group type: COMPARATOR
Intervention: Cold antegrade cardioplegia
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Warm retrograde cardioplegia
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Tepid retrograde cardioplegia
Number of subjects: 72

Group type: COMPARATOR
Intervention: Cold retrograde cardioplegia
Number of subjects: 72
Study: 3555386

Group type: EXPERIMENTAL
Intervention: Adjunctive imipramine hydrochloride treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 1790567

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine (1 mg/kg)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Intravenous normal saline (placebo)
Number of subjects: 25
Study: 405029

Group type: EXPERIMENTAL
Intervention: Meptazinol administered rectally
Number of subjects: 0